anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Jaberi-Elahi syndrome is an extremely rare genetic disease caused by pathogenic variants in GTPBP2. The core symptoms of this disease are intellectual disability, motor development delay, abnormal reflexes, skeletal abnormalities, and visual impairment. In this study, we describe a three-year-old girl with a novel homozygous variant in GTPBP2 and a phenotype overlapping with Jaberi-Elahi syndrome. This variant (NM_019096.5:c.1289T > C, p.Leu430Pro) was identified by Whole Exome Sequencing and confirmed by Sanger sequencing although remains classified as VUS based on ACMG criteria. The proband demonstrated motor and intellectual developmental delay, muscle weakness, language disorder, facial dysmorphism, and poor growth. Hitherto, twenty-seven individuals with Jaberi-Elahi syndrome have been reported in the literature. This study, describes a review of the symptoms related to the Jaberi-Elahi syndrome. A large numbers of patients manifest motor development delay (26/28), sparse hair (26/28), and speech disorder (24/28). Moreover, a significant fraction of patients suffer from intellectual disability (23/28), hypotonia (23/28), skeletal problems (23/28), and visual impairment (18/28). In spite of previous patients, the proband in this study did not exhibit any skeletal abnormalities. In summary, we present evidence implicating a novel missense variant in Jaberi-Elahi syndrome, expanding and refining the genetic spectrum of this condition.
The invention provides a system for accessing business data stored in one or more databases by a user. The system includes a means for presenting a user with a plurality of components with each component representing a discrete element of the business model, having a defined relationship with each other component, and including a plurality of information objects. Each information object represents an instance of the component business element and can be defined by a set of attributes and behaviors. The system further provides means for user selection of a first one of the plurality of components, for user selection of a first one of the plurality of information objects from the first component, and for instantiating the first information object. The user can then manipulate the first information object to cause the object to interact with any of the other components. The system then generates a report showing information objects of the other component which represent instances of the other component that are related to the first information object.
The intervention group will receive Myofascial Massage Therapy specific to breast/chest/shoulder of the affected side(s). These massages will include a variety of techniques specifically aimed at reducing pain, inflammation, and tissue sensitivity while also increasing mobility by breaking up scar tissue and thick fibrosis. The intervention massages will include the following specific techniques: skin glide, j stroking, vertical stroking, strumming, fascial stretch, circular friction, deep fascial restriction release, arm pull, side latissimus dorsi stretch, twisting, moist heat application, cold therapy, and lymphatic drainage. These massages will be twice a week at 30 minutes per massage for a period of 2 months after study enrollment.
Unscheduled Bleeding and Spotting

Unscheduled (breakthrough or intracyclic) bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different contraceptive product.

In clinical trials of norgestimate and ethinyl estradiol Tablets 0.25mg/0.035mg, the frequency and duration of breakthrough bleeding and/or spotting was assessed in 1,647 patients (21,275 evaluable cycles) and 4,826 patients (35,546 evaluable cycles), respectively. A total of 100 (7.5%) women discontinued norgestimate and ethinyl estradiol Tablets 0.25mg/0.035mg, at least in part, due to bleeding or spotting. Based on data from the clinical trials, 14-34% of women using norgestimate and ethinyl estradiol Tablets 0.25mg/0.035mg experienced unscheduled bleeding per cycle in the first year. The percent of women who experienced breakthrough/unscheduled bleeding tended to decrease over time.

Amenorrhea and Oligomenorrhea

Women who use Mono-Linyah may experience amenorrhea. Some women may experience amenorrhea or oligomenorrhea after discontinuation of COCs, especially when such a condition was pre-existent.

If scheduled (withdrawal) bleeding does not occur, consider the possibility of pregnancy. If the patient has not adhered to the prescribed dosing schedule (missed one or more active tablets or started taking them on a day later than she should have), consider the possibility of pregnancy at the time of the first missed period and take appropriate diagnostic measures. If the patient has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy.
<P>PROBLEM TO BE SOLVED: To provide a transport apparatus having a means for shaking a blood preparation, especially a platelet-based preparation during its transportation.  <P>SOLUTION: The transport apparatus 1 for the blood preparation comprises a thermal insulation container 3 for transporting, a temperature control unit 4 as a temperature control means for keeping the thermal insulation container 3 at a predetermined temperature, and a shaking unit 5 as a shaking means installed in the thermal insulation container 3. In this apparatus 1, the shaking unit 5 has a substrate 13 as the base, wherein the respective dimensions L1 and W1 in the cross direction and the depth direction on the horizontal surface of the substrate 13 are nearly equal to those L2 and W2 on the inner bottom surface of the transport house 3. Thus, by operating the shaking unit 5, the function of the platelet-based preparation P can be maintained. Besides, with a combination of the shaking unit 5 with the single-purpose thermal insulation container 3, by shaking the platelet-based preparation P under a predetermined container temperature condition, the optimal quality maintenance for the platelet-based preparation P can be accomplished.  <P>COPYRIGHT: (C)2008,JPO&INPIT
PURPOSE: Hypervascular spinal metastatic malignancies can cause severe pain and intraoperative bleeding and selection of appropriate treatment can be challenging. This study aimed to observe the short-term efficacy and safety of Iodine-125 brachytherapy (125I BT) combined with preoperative transcatheter arterial chemoembolization (TACE) for hypervascular spinal metastasis.
METHODS: This study included a total of 33 patients (39 lesions) with hypervascular spinal metastasis. All of them carried out a regimen of TACE followed by 125I BT under CT guidance. A brachytherapy planning system has been utilized for the purpose of designing treatment plans and optimizing dose distribution. Pain relief was evaluated using a numeric rating scale (NRS) and intraoperative bleeding was recorded. Follow-up was conducted for 6 months to observe the local control rate and clinical complications.
RESULTS: All patients tolerated combined treatment well and intraoperative blood loss of every patient was not more than 10 ml. The 2- and 6- month local disease control rates were 92.3% and 83.8%. The NRS scores for thirty-three tumor patients before surgery and after one week, two, and six months of surgery were recorded as 7.33 ± 1.80, 7.39 ± 1.89, 3.15 ± 2.35, and 4.16 ± 2.15, respectively. The NRS score 2 months after treatment was found considerably lower in comparison to the NRS score before operation (p < 0.05).
CONCLUSIONS: According to our findings, 125I BT as well as preoperative TACE leads to perioperative hemostasis, pain alleviation, and reduced tumor burden, indicating that this combined treatment could be effective and promising for hypervascular spinal metastases.
AIMS: This study aimed to evaluate the association between memory impairment and its risk and protective factors, focusing on demographic and health-related variables among older adults in Indonesia.
METHOD: The data analyzed were the Indonesian Family Life Survey-5 (IFLS-5) using cross-sectional variables of 4236 older adults aged 60 years and over included in the 2015 round. Memory impairment was assessed by immediate word list recall from the Telephone Interview for Cognitive Status (TICS). Sociodemographic factors and multiple health variables were included as predictors. Data were analyzed using frequency analyses bivariate and stepwise logistic regression tests.
RESULT: Among 4236 older adults, 49.7% were male and 50.3% were female. Stepwise backward analyses showed that memory impairment was independently associated with older age, being female, or not in a union (unmarried, separated, divorced, or widowed), having obtained low levels of education, living in a rural area, reporting low life satisfaction, low social capital, higher dependency, and having clinical depression. Only moderate (but not high or low) physical activity levels were associated with a lower risk. Being underweight increased the risk, but being overweight/obese (as assessed by BMI) protective factors for a lower immediate recall score.
CONCLUSION: Increasing education and continued engagement of older adults in psychosocial activities, including moderate physical activity, improving mental health, preventing weight loss, and maintaining functional ability to decrease dependency, are associated with increased episodic memory, especially in non-married and older women in rural areas of Indonesia.
Surgical septal myectomy remains the gold standard for the treatment of hypertrophic obstructive cardiomyopathy. However, conventional septal myectomy is hindered by the demanding expertise that is needed to sufficient relieve the obstruction of the left ventricle outflow tract while guarantee safety. To increase the visualization and minimize the surgical injury of conventional septal myectomy, we have invented a novel beating-heart myectomy device. Through a mini-thoractomy, septal myectomy could be accomplished via a transapical access in the beating heart using the beating-heart myectomy device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outflow tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor sufficient relief of left ventricle outflow tract obstruction and mitral regurgitation, while preventing iatrogenic injuries. After transapical beating-heart septal myectomy, patients is scheduled to be seen for follow-up visits at discharge (about 7 days post operation) and 3 months.
If the creatinine clearance rate \> 30ml/min, the initial dose of bivalirudin is 0.04mg/kg/h. If the creatinine clearance rate\<30ml/min or the patients who have received renal replacement therapy (CRRT), the initial dose of bivalirudin is 0.02mg/kg/h, and the dose is adjusted according to APPT to maintain APTT at 40-60s. After bivalirudin started, APTT was checked every 4 hours. If APTT was in the target range twice in a row, it was re-examined every 12 hours.
Some authors have investigated, in a retrospective fashion, the use of routine shave margins, where surgeons routinely take additional margins at the time of the initial partial mastectomy as a means of obtaining negative margins. While these retrospective studies have found that positive margin rates declined using this technique, opponents to this technique wonder if this truly results in a higher negative margin rate without compromising cosmesis or increasing tissue volume removed. As these studies were retrospective, it was possible that the initial resection was smaller than what those who do not routinely take shave margins would resect. No one had evaluated the impact of further resection on operative time, nor in a blinded fashion, evaluated cosmesis. Further, there had yet to be a prospective study to evaluate the impact of this on local recurrence rates. Hence, the investigators performed a prospective randomized controlled trial of this technique at Yale. The data from this study, published in the New England Journal of Medicine, found that the technique cut positive margin and re-excision rates in half. Some wondered, however, about the external generalizability of these findings, particularly in non-academic settings. Hence, a multicenter trial to validate these findings is warranted.
<P>PROBLEM TO BE SOLVED: To provide an oily cosmetic which gives a soft touch, when coated, can uniformly be spread, does not make the unevenness of skins and lips prominent, forms cosmetic films controlling oil gloss and having naturally beautiful appearances, prevents dryness, and is excellent in emollient effect.  <P>SOLUTION: This oily cosmetic is characterized by comprising (A) a fructooligosaccharide fatty acid ester having a saccharide-average polymerization degree of 10 to 60 and a fatty acid esterification degree per monosaccharide unit of ≥2.2, (B) a long chain alkyl group-containing partially cross-linked organopolysiloxane, and (C) a liquid oil except silicone oils. Further, a solid oil may be contained. The liquid oil (C) except the silicone oils is preferably a liquid oil containing at least one or more ester bonds in the molecule, or especially preferably an ester oil which is liquid at the ordinary temperature, has hydroxy groups in the molecule and has a mol.wt. of 300 to 1,000.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The present invention relates to a medicine composition for lowering blood fat. The present invention contains atorvastatin, pantethine and flavonoid. Dressing or additive agents which are allowed by pharmacy are added. The medicine composition can be applied to not only prepare medicine for improving the content of cholesterol in blood but also prepare an improvement agent for lipid in blood. The composition of the present invention is verified through research that the medicine composition can obviously reduce the content of cholesterol in blood; the effect of the medicine composition is better than the effect of each ingredient singly used; the dosage of the atorvastatin can be reduced, and therefore, the side effect caused by high concentration of taking medicine for a long time can be greatly reduced. The present invention provides medicine for treating hyperlipoidemia, which has outstanding curative effect, for the clinic.
PROBLEM TO BE SOLVED: To obtain the subject external preparation, containing a specific n-6- based unsaturated fatty acid, having sufficient treating effect on bone disease of artificial dialysis patent, effective on alleviation of pain, free from adverse effect and capable of using for a long period. SOLUTION: This external preparation contains one kind or two or more kinds of compounds selected from γ-linolenic acid, dihomo-γ-linolenic acid and their derivatives. Furthermore, γ-linolenic acid is preferably γ-linolenic acid- containing oil and fat extracted from yeast cell body of the genus Mortierella. A content (converted to an amount of γ-linolenic acid in the case of dihomo-γ- linolenic acid and each derivative) of the γ-linolenic acid is usually preferably 2-20wt.% based on the external preparation. The external preparation is preferably used by applying to a part of lesion once or twice per day, spreading the applied agent and lightly massaging the applied part. An amount of the γ-linolenic acid is preferably 0.4 to 10mg/10cm2 (skin area)/day.
The high level of oxidative stress induced by angiotensin II (AngII) is the main pathophysiological process that promotes the proliferation and migration of vascular smooth muscle cells (VSMCs) and induces vascular remodeling. LncRNA metastasis-related lung adenocarcinoma transcript 1 (MALAT1) has been determined to play an important role in the modulation of oxidative stress and the development of cardiovascular diseases. Nevertheless, the function and underlying mechanism of MALAT1 in restenosis induced by hypertensive angioplasty remain unclear. AngII increased the expression of MALAT1 in VSMCs. We found that antisense oligonucleotide lncRNA MALAT1 (ASO-MALAT1) could inhibit AngII-induced reactive oxygen species production and VSMCs proliferation and migration by inducing the expression of glutathione peroxidase 4 (GPX4), which can be reversed by siRNA-GPX4. GPX4 overexpression can inhibit the proliferation and migration of VSMCs induced by AngII. In addition, we found that the process by which MALAT1 knockdown induces GPX4 expression involves nuclear factor erythrocyte 2-related factor 2 (Nrf2). Overexpression of Nrf2 can increase the expression of GPX4, and downregulation of GPX4 by ML385 (Nrf2 inhibitor) blocked the protective effect of ASO-MALAT1 on AngII-induced proliferation and migration of VSMCs. Ferrostatin-1 (Fer-1, ip 5 mg/kg per day for 2 weeks), a GPX4 agonist, significantly inhibited neointimal formation in spontaneously hypertensive rat by the inhibition of oxidative stress. In conclusion, these data imply that ASO-MALAT1 suppresses the AngII-induced oxidative stress, proliferation, and migration of VSMCs by activating Nrf2/GPX4 antioxidant signaling. GPX4 may be a potential target for the therapeutic intervention of hypertensive vascular restenosis.
The present invention comprises methods for preparing a hybrid vaccine, which consists of an autologous solution of genetically modified mesenchymatic germ cells with human neuroprotective genes (siRNA) and transplantation thereof in the brain for the therapy of polyglutamine diseases for the treatment of the Huntingtons disease, and Spinocerebellar ataxia type 1 and Spinocerebellar ataxia type 3 by transfection of germ cells with gene expression vectors or lentiviruses containing viral gene expression vectors for the human neuroprotective genes. The neuroprotective genes are the (siRNA) CRK, DNAJB4, EIF2S3, GCA, NEK8, PSMB6, and PUM1, HTT, TBP, ATXN1, AR, Bdnf, AKT1, XRCC6, FUS, STUB1, HSPA1A, SGK1. The mesenchymatic cells constitute an interesting class of germ cells, since they can be easily isolated from bone marrow. These cells are very important in regenerative medicine, since they are pluripotent and can differentiate in various tissues. The genetically modified germ cells expressing neuroprotective proteins may aid in neuron survival, reducing the polyQ-mediated cytotoxicity and clearing the polyQ aggregates from the brain. These methods may be particularly useful for the treatment of polyglutamine diseases (Huntingtons disease, and Spinocerebellar ataxia type 1 and Spinocerebellar ataxia type 3). The present invention also comprises a method for transplanting genetically modified mesenchymatic germ cells in the brain for the prevention and/or treatment of neurological disorders associated with mutated proteins containing major polyglutamine extensions. The present invention describes the methods and the composition of a hybrid vaccine consisting of the product from the chemical reaction of a bipolar coupling of a polyQ peptide and the HSP60 peptide in molar ratio 1:1, which may elicit a strong immune response against the protein aggregates formed by mutated proteins with dominant extensions and polyglutamine inserts in the brain. The present hybrid vaccine may be proved particularly useful in the therapy of polyglutamine diseases for the treatment of Huntingtons disease, Spinocerebellar ataxia type 1 and Spinocerebellar ataxia type 3. The present invention also provides a hybrid vaccine composition containing an autologous solution of genetically modified mesenchymatic germ cells with the (siRNA) of consensus common coding sequences (CCCS) of the human neuroprotective genes (siRNA) CRK DNAJB4 EIF2S3 GCA NEK8 PSMB6 PUM1 and (siRNA) of consensus common coding sequences (CCCS) of genes HTT TBP ATXN1 AR Bdnf AKT1 XRCC6 FUS STUB1 HSPA1A SGK1 and a mixture of synthetic peptides comprising the PQ1 (SEQ ID.:1) and p458h (SEQ ID:2) peptides in a synthetic dendrimer nanoparticle composition carrier.
Hydromorphone Hcl 4 milligram (mg) Tab 2 times after surgery as basic medication. Hydromorphone Hcl 2.6mg maximum 2 per 24h when numeric rating scale (NRS) \> 5.
Postmenopausal women often experience hormonal changes and shifts in fat composition, affecting weight gain and obesity. Understanding the link between hormones, especially estrogen and leptin, is key to managing weight and lowering disease risk in menopausal women. The aim of this study was to compare the levels of leptin and estrone in menopausal women with normal weight and obesity. A cross-sectional study was conducted on menopausal women, either normal body mass index (BMI) or obese, at H. Adam Malik General Hospital, Medan, Indonesia. Blood samples were collected to measure leptin and estrone levels using the enzyme-linked immunosorbent assay (ELISA) method. The differences in leptin levels between groups were analyzed using the Wilcoxon test, while the correlation between BMI and leptin was examined using the Pearson correlation test. The disparity in estrone levels in both groups was analyzed using the Mann-Whitney test and the correlations between variables were assessed using the Spearman or Pearson correlation tests as appropriate. The mean leptin levels in normal BMI and obesity groups were 17.73±4.96 and 25.46±12.95 ng/mL, respectively, and were statistically different (p=0.006). The mean estrone levels in menopausal women with normal BMI and obesity were 943.23±391.79 and 851.38±282.23 ng/mol, respectively and were not statistically different (p=0.564). A significant positive correlation was found between BMI and leptin level (r=0.59; p<0.001), while BMI and estrone were not significantly correlated (r=0.083; p=0.559). In conclusion, leptin level was significantly different between BMI groups and had a strong positive correlation with BMI. This finding could be an important insight in body weight management and disease risk prevention in menopausal women.
The invention relates to the field of healthcare food and specifically relates to an American ginseng schisandra chinensis health product. The American ginseng schisandra chinensis health product is prepared by taking the following raw materials by weight part: 80-100 parts of American ginseng saponin, 8-10 parts of schizandrin, 1500-2500 parts of American ginseng polysaccharide and 2500-3500 parts of dextrin. The mice immunological enhancement effect of the combination of American ginseng saponin and schizandrin is obviously better than that of single drug and the advantage of compatibility of medicines is presented. The extraction efficiency of American ginseng saponin is greatly promoted by limiting different parameters of American ginseng extraction. An ethyl alcohol reflux extraction method is adopted for extracting schizandrin and the reflux parameters are limited, so that the extraction efficiency of schizandrin is greatly increased. The vacuum concentration and vacuum microwave drying are adopted for drying, so that the cost is lowered, the drying efficiency is increased and the effective contents of American ginseng saponin and schizandrin are obviously increased.